What Happened?
Boston, MA-based Sensei-Biotherapeutics Promoted Erin Colgan as Chief Financial Officer
About the Company
Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.
About the Person
Erin Colgan is Chief Financial Officer at Sensei Biotherapeutics. Previously, Erin held various senior HR leadership roles in the industry.
Info Source
News
Short Profile